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MitochondrionYeast cells deﬁcient in the yeast frataxin homolog (Yfh1p) accumulate iron in their mitochondria. Whether
this iron is toxic, however, remains unclear. We showed that large excesses of iron in the growth medium did
not inhibit growth and did not decrease cell viability. Increasing the ratio of mitochondrial iron-to-Yfh1p by
decreasing the steady-state level of Yfh1p to less than 100 molecules per cell had very few deleterious effects
on cell physiology, even though the mitochondrial iron concentration greatly exceeded the iron-binding
capacity of Yfh1p in these conditions. Mössbauer spectroscopy and FPLC analyses of whole mitochondria or
of isolated mitochondrial matrices showed that the chemical and biochemical forms of the accumulated iron
in mitochondria of mutant yeast strains (Δyfh1, Δggc1 and Δssq1) displayed a nearly identical distribution.
This was also the case for Δggc1 cells, in which Yfh1p was overproduced. In these mitochondria, most of the
iron was insoluble, and the ratio of soluble-to-insoluble iron did not change when the amount of Yfh1p was
increased up to 4500 molecules per cell. Our results do not privilege the hypothesis of Yfh1p being an iron
storage protein in vivo.NRS-Université Paris Diderot,
cedex 13, France. Tel.: +33
iderot.fr (E. Lesuisse).
ll rights reserved.© 2010 Elsevier B.V. All rights reserved.1. Introduction
Friedreich's ataxia is themost common hereditary recessive ataxia.
The gene responsible for this neurodegenerative diseasewas cloned in
1996 [1]. The corresponding protein (frataxin) was found to be a
small, highly conserved mitochondrial protein. Similar crystal or NMR
structures have been resolved for the human, yeast and bacterial
homologs of this protein [2].
It is now generally accepted that frataxin (Yfh1p in yeast) is one of
the components of the mitochondrial [Fe–S] cluster machinery, acting
either as an iron donor, or more generally as a chaperone interacting
in an iron-dependent manner with the desulfurase/scaffold proteins
involved in [Fe–S] assembly [3,4]. However, the precise role of frataxin
is more difﬁcult to deﬁne than that of other components of the [Fe–S]
cluster machinery, maybe because frataxin is a multifunctional
protein (for a recent review, see [5]). Indeed, the lack of frataxinresults in direct or indirect defects in many pathways other than [Fe–
S] biogenesis, including heme synthesis [6,7], oxidative stress defense
[8,9], apoptosis [10] and mitochondrial iron homeostasis [11].
This paper focuses on the relationship between Yfh1p and iron.
The yeast frataxin (Yfh1p) can bind iron in vitro in the monomeric
[12], trimeric [13] or oligomeric/multimeric form [14]. The biochem-
ical and structural aspects of iron-binding by frataxin have been
studied extensively (reviewed in [2]). Yfh1p monomers can self-
assemble in vitro in an iron-dependent manner to yield a macromo-
lecular complex with physical features consistent with a role in iron
storage [15]. The assembly of Yfh1p in vitro is a stepwise process that
requires the presence of Fe(II). Fe(II) is converted into Fe(III) during
the oligomerization process, yielding ferritin-like particles of 24 or 48
subunits. Yfh1p monomers are arranged into trimers within these
particles, which contain up to 2400 iron atoms [13–16]. Frataxin has
been compared to ferritin, despite major structural differences, since
both proteins can convert redox-active iron into an inert mineral
through ferroxidation activity [14]. These ﬁndings led several authors
to suggest that frataxin not only promotes the biogenesis of iron-
containing proteins (throughmonomeric or small oligomeric forms of
the protein), but also detoxiﬁes surplus iron in the mitochondria
(through the formation of ferritin-like frataxin particles), thereby
mediating a major antioxidant mechanism [17,18].
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of frataxin demonstrated in vitro play a role in, or are required for, in
vivo function. In a recent study, Gakh et al. [18] showed that Yfh1p
oligomerization in vivo is induced by iron, heat stress and
overproduction of the monomer. However, they did not show iron
storage in Yfh1pmultimers in vivo. We also previously observed that
overexpression of YFH1 resulted in an increased level of Yfh1p
oligomerization in vivo, but the shift in Yfh1p distribution after gel
ﬁltration was not accompanied by a shift in iron distribution,
suggesting that iron was not stored in the multimers [19]. In the
present study, we investigate this issue further by analyzing the
physico-chemical properties of iron accumulated in the mitochon-
dria of different yeast strains in the presence of various amounts of
Yfh1p. We conclude that Yfh1p did not store iron in vivo under our
experimental conditions.2. Material and methods
2.1. Yeast strains and growth conditions
The strains used in this study were YPH499 (wild-type; MATa
ura3-52 lys2-801 ade2-101 trp1-Δ63 his3-Δ200 leu2-Δ1 cyh2),
YPH499Δyfh1 (Δyfh1; Δyfh1::TRP1), BY4741 (wild-type; MATa
his3D1 leu2D0 met15D0 ura3D0), BY4741Δggc1 (Δggc1; Δggc1::
kanMX4), BY4741Δggc1-YFH1 (Δggc1 transformed with the multi-
copy plasmid pRS423, expressing YFH1 under the control of its native
promoter, thus resulting in the overexpression of YFH1 in this strain)
and BY4741Δssq1 (Δssq1; Δssq1::kanMX4). To construct the strain
with YFH1 under estradiol control (ERyfh1), the starting strain
YPH499 was subjected to a promoter swap by transformation with
a His3MX-pGAL1 cassette, thereby placing YFH1 under GAL1 control.
In this strain, the GAL4 gene was replaced with KanMX (Δgal4::
KanMX), and transformants selected for geneticin (G418) resistance
and grown in anaerobic conditions. Next, the pGEV2-LEU2 centro-
meric plasmid was introduced by anaerobic transformation in the
presence of 5 µM estradiol [20,21]. In this plasmid, the beta estradiol
inducible activator GAL4-ER-VP16 is expressed from a low level
constitutive MRP7 promoter [20,21]. Subsequently cultures were
maintained aerobically in the presence or absence of various
concentrations of estradiol. The cells grew robustly at 5 µM estradiol
but poorly in the absence of estradiol. Unless otherwise stated, cells
were grown aerobically in deﬁned medium (6.7 g/l yeast nitrogen
base without amino acids, iron or copper, and containing 0.1% glucose,
2% rafﬁnose and 0.8 g/l amino acids). The deﬁned media were
supplemented with 5 µM CuSO4 and with various amounts of iron, in
the form of ferric citrate.2.2. Mössbauer spectroscopy
57Fe Mössbauer experiments were operated using a 50 mCi
source of 57Co(Rh) (AREVA). The spectra were recorded either on a
zero-ﬁeld Mössbauer spectrometer equipped with a custom-made
cryostat or on a strong-ﬁeld Mössbauer spectrometer equipped with
an Oxford Instruments Spectromag 4000 cryostat containing an 8 T
split-pair superconducting magnet. Both spectrometers were oper-
ated in a constant acceleration mode in transmission geometry. The
14.4 keV g-rays were detected by means of a proportional counter
and the spectra were recorded on a 512 multichannel analyzer
working in the multiscaling mode. The temperature of the sample
was measured with a Pt resistor. The system was calibrated with a
metallic iron foil absorber at room temperature, and all velocity
scales and isomer shifts are referred to the iron standard. Analysis of
the data was performed with the program WMOSS (WEB Research,
Edina, MN).2.3. Iron uptake and enzyme assays
Iron uptake was measured in microtiter plates, after incubating
cells for 30 min in minimum medium with 1 µM 55Fe(II)-ascorbate,
as previously described [22]. The speciﬁc activity of iron was
29,600 MBq/mg. The in-gel aconitase assay was performed as
previously described [23].2.4. Immunochemical reagents and western blot analysis
The anti-Yfh1 rabbit antibody was generated and checked as
previously described [24]. Samples were incubated in Laemmli
sample buffer for 5 min at 100 °C. They were then separated by
SDS-PAGE in a 13% polyacrylamide gel and the protein bands were
electrotransferred onto a Hybond nitrocellulose membrane (Amer-
sham Pharmacia Biotech, Piscataway, USA). Primary antibody
binding was detected, after incubation with peroxidase-conjugated
secondary antibody, with chemiluminescent substrate (Supersignal
West from Pierce, Rockford, USA). Signals were quantiﬁed using
ImageJ software (http://rsb.info.nih.gov/ij/). For the oxyblots,
carbonylated proteins were detected and analyzed following deriv-
atization of protein carbonyl groups with 2,4-dinitrophenylhydra-
zine (DNPH) (Oxyblot kit, Abcys, Paris, France). The primary
antibody used for western blot analysis was raised against dinitro-
phenylhydrazone (DNP).2.5. Cell fractionation
Mitochondrial and cytosolic fractions were isolated after treat-
ment of cells with zymolyase, followed by lysis of the protoplasts in
0.6 M sorbitol (buffered with TRIS 50 mM, pH 7.8), in the presence of
protease inhibitors (Protease inhibitor cocktail, P8215, Sigma) as
described previously [25]. The purity of the mitochondrial fraction
was estimated by the activity of cytochrome oxidase, as previously
described [25]. Submitochondrial fractionation was carried out as
previously described [26], by hypotonic shock followed by sonication
(1 min, 3 times) in 10 mM HEPES buffer (without EDTA; pH 7.2).
Total, soluble and insoluble iron content in whole mitochondria and
in mitochondrial matrices was measured by scintillation counting in
the corresponding fractions.2.6. Fast protein liquid chromatography (FPLC)
The distribution of iron-containing proteins from the mitochon-
drial matrix was analyzed by size-exclusion chromatography.
Mitochondria (from cells grown with 1 µM 55Fe(III)-citrate) were
lyzed in hypotonic buffer (HEPES 10 mM, pH 7) and sonicated for 30 s
before being centrifuged at 25,000 g for 30 min. Supernatants
(0.5 ml, 20 mg protein/ml) were loaded onto a Superdex 200 10/
300 GL column (GE Healthcare) and proteins were eluted at a ﬂow
rate of 0.2 ml/min with 50 mM HEPES and 140 mM NaCl, pH 8.0,
using the FPLC system ÄKTA puriﬁer UPC 10 (GE Healthcare).
Fractions (0.2 ml) were collected and the radioactivity of each
fraction was counted in a microplate scintillation counter (MicoBeta
TriLux). The column was calibrated with a gel ﬁltration standard
(Bio-Rad). Fractions were concentrated and equal volumes of each
fraction were analyzed by SDS-PAGE and western blotting.2.7. Other
Low-temperature absorption spectra (−191 °C) of whole cells
were recorded as previously described [27,28].
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3.1. Toxicity of mitochondrial iron in Δyfh1 cells
The amount of iron accumulated in the mitochondria of Yfh1p-
depleted cells is directly proportional to the iron concentration in the
growth medium [29]. In the model assuming a major role played by
Yfh1p in mitochondrial iron storage [15], the disruption of YFH1
would increase the concentration of unbound iron in the mitochon-
drial matrix, explaining the increased sensitivity of cells to oxidative
stress. Thus, mitochondrial iron would be toxic in Δyfh1 cells, due to
the inability of these cells to store this iron in the proper form [13].
This model is frequently referred to in the literature; however, to our
knowledge there is no study clearly showing a toxic effect of iron in
Yfh1p-depleted cells. We tested the effect of increasing the concen-
tration of iron in the medium (in the range of 1 to 2500 µM) on the
growth of wild-type and Δyfh1 cells, and on cell viability (Fig. 1). Our
results showed that the toxicity of iron was surprisingly low in Δyfh1
cells: excess iron even improved the growth of Δyfh1 cells, an effect
that depended on the carbon source used for growth. When rafﬁnose
was used, iron (up to a concentration of 250 µM) clearly stimulatedFig. 1. The effect of iron on the growth and viability of Δyfh1 and wild-type cells. A and
B: cell growth. Wild-type (closed circles) and Δyfh1 (open circles) cells were grown in
deﬁned medium containing 2% rafﬁnose (A) or 2% glucose (B) as the carbon source, in
the presence of 1–2500 µM of ferric citrate (1:50). Cells were inoculated at an OD600nm
of 0.05 (A) or 0.015 (B). The growth rate was estimated by measuring the OD600nm of
the cultures after 40 h incubation at 30 °C. Mean±SD from 4 experiments. C: Δyfh1 cell
viability. Δyfh1 cells were grown as above (deﬁned medium, glucose 2%) without iron
(open circles) or in the presence of 25 µM (triangles), 250 µM (squares) or 2500 µM
(closed circles) of ferric citrate (1:50). Cell viability was estimated (from the day of
inoculation to 7 days after inoculation) by plating 100 cells (counted in a Malassez cell)
on YPD-agar and by counting the number of growing colonies. Mean±SD from 3
experiments.the growth of Δyfh1 cells, but not of wild-type cells (Fig. 1A). This
stimulating effect of iron on the growth of Δyfh1 cells was less marked
when glucose was used as the carbon source. However, iron added in
large excess clearly had a weaker toxic effect in Δyfh1 cells than in
wild-type cells (Fig. 1B). The effect of iron on the viability of stationary
phase Δyfh1 cells was stronger than the effect of iron on cell growth
(Fig. 1C). After 7 days of growth, more than 70% of the wild-type cells
were still viable, whatever the iron concentration added to the
medium (0–2,500 µM; data not shown). In the same conditions,
nearly 100% of Δyfh1 cells were not viable when no iron was added in
the medium, while about 40% of the cells remained viable at the
highest iron concentrations (250–2500 µM; Fig. 10C). In contrast,
copper added to the growth medium was much more toxic to Δyfh1
cells than to wild-type cells: the growth of Δyfh1 cells started to be
inhibited at concentrations of CuSO4 of 25 µM and above, whereas the
growth of wild-type cells remained unaffected below CuSO4 concen-
trations of 250 µM (data not shown). Thus, iron is less toxic to Yfh1p-
depleted cells than would be expected if iron accumulated in a redox-
active form. We previously showed that most of the iron accumulated
in the mitochondria of Δyfh1 cells was present in an amorphous
precipitated form, unavailable for heme synthesis [6].
3.2. Physiological effects of increasing the iron-to-Yfh1p ratio by
decreasing the steady-state expression of YFH1
We studied the effect of strongly decreasing the production of
Yfh1p in a strain in which transcription of the YFH1 gene was
controlled by the concentration of estradiol in the growth medium
(strain ERyfh1). There are several advantages of this system over
systems with YFH1 under the control of the GAL1 or gal1*
(compromised GAL1) promoters [30]. First, repression of YFH1
transcription does not require changing the carbon source from
galactose to glucose, which leads to catabolic repression and
interferes with mitochondrial metabolism. Second, in the estradiol
system, YFH1 transcription is not simply on or off, as it is in the
galactose system. Rather, different concentrations of estradiol in the
medium allow different steady-state rates of transcription to be
obtained [20,21].
Quantitative immunoblotting (using puriﬁed Yfh1p as a standard)
allowed us to estimate the number of Yfh1p molecules per cell for
each condition tested, as previously described [19]. Fig. 2 shows the
amount of Yfh1p per cell for the ERyfh1 strain, as a function of
estradiol concentration in the medium. The amount of Yfh1p ranged
from nearly 0 to about 1300 molecules per cell (Fig. 2). At a
concentration of 2.5 nM estradiol in the medium, the amount of
Yfh1p was lower than 100 molecules per cell, reaching about
1300 molecules per cell at a concentration of 10 nM estradiol, similar
to the level of Yfh1p found in wild-type cells (Fig. 2; [19]). The
phenotype of cells containing 100 to 1300 molecules Yfh1p per cell is
shown in Fig. 3. Wild-type levels of aconitase activity were recovered
from cells showing the lowest amounts of Yfh1p (Fig. 3A), whereas
cytochrome synthesis was recovered progressively, with wild-type
levels being reached at levels of Yfh1p similar to those found in wild-
type cells (Fig. 3B). Thus, as we previously showed for theFig. 2. Estradiol-dependent production of Yfh1p. The amount of Yfh1p in wild-type
(WT), and Eryfh1 (ER) cells, grown overnight in deﬁned medium, was assessed by
western blotting. The expression of YFH1 in ERyfh1 cells was modulated by adding 0,
2.5, 5 or 10 nM estradiol to the growth medium. In each case, whole cell extract from
15×106 cells was loaded onto the gel for SDS-PAGE and western blotting.
Fig. 3. Phenotype of cells expressing various amounts of Yfh1p. Wild-type (WT),
Δyfh1 and ERyfh1 (ER) strains were grown overnight in deﬁned medium containing
0–10 nM estradiol before analyses were carried out. A. Aconitase activity, determined
on a non-denaturing gel loadedwith 150 µg of whole cell extract. B. Low-temperature
spectra of whole cells; α bands of cytochromes c, c1 and b are indicated by arrows;
spectra are from Δyfh1 cells (1), from ERyfh1 cells grown with 0 (2), 2.5 (3), 5 (4) or
10 nM (5) estradiol, and from wild-type cells (6). C. Iron accumulation in cells
incubated with 1 µM 55Fe(II)-ascorbate. D. Protein oxidation status in puriﬁed
mitochondria (oxiblot). Carbonylated proteins were detected after SDS-PAGE (30 µg
protein/lane) and western blotting as described in Section 2.
Fig. 4. Production of Yfh1p by cells of different strains. Cells were grown overnight in
deﬁned medium, and whole cell extracts from 15×106 cells were loaded onto gels for
SDS-PAGE and western blotting. We checked that all Yfh1p produced was from the
mitochondria (not shown).
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also differentiate between phenotypes related to [Fe–S] cluster
synthesis and those related to heme synthesis. Mitochondrial iron
was also recovered at nearly wild-type levels in cells showing the
lowest levels of YFH1 expression (Fig. 3C). This observation is
consistent with a tight relationship between the biogenesis of
mitochondrial iron–sulfur proteins and the regulation of iron
uptake/distribution [31]. Additionally, the amount of oxidatively
modiﬁed (carbonylated) proteins also returned to nearly wild-type
levels in cells with the lowest levels of YFH1 expression (Fig. 3D).
In a previous study, we showed that the number of “free iron”
atoms is between 100 and 500 times greater than the number of
Yfh1p molecules in the mitochondrial compartment of wild-type cells
[19]. In the present study, we generated yeast cells with a diminished
steady-state level of Yfh1p giving rise to a mitochondrial iron-to-
Yfh1p ratio more than 10 times higher thanwild-type. This resulted in
very few deleterious effects on cell physiology (Fig. 3). Other previous
studies have shown that Yfh1p cellular levels can be signiﬁcantly
reduced before the adverse effects on cell growth are detected, even in
the presence of excess intracellular iron [30,32]. Thus, if Yfh1p were
an iron storage protein protecting cells against iron-induced oxidative
damage, these ﬁndings suggest that this detoxiﬁcation by Yfh1p must
be a highly efﬁcient process, with very low amounts of Yfh1p (less
than 100 molecules per cell) detoxifying large amounts of “free iron”
(1000–5000 times more iron than frataxin). However, such a process
seems unlikely, given that the highest estimated iron-to-Yfh1p ratio
in a Fe–Yfh1 multimeric complex gives only 50 atoms of iron per Yfh1
subunit [14,15,33]. An alternative explanation of these data would
imply that Yfh1 behaves more “dynamically” than ferritin, binding
iron transiently to deliver it with very high efﬁciency to aconitase. We
investigated these questions further, comparing different yeast strainsthat accumulate iron in the mitochondria in the presence of different
amounts of Yfh1p.
3.3. Solubility of iron in the mitochondria of different yeast strains
We compared the soluble and insoluble iron contents of
mitochondria isolated from various yeast strains with different iron-
to-Yfh1p ratios. The soluble iron pool is deﬁned as the pool of iron in
the mitochondrial matrix that remains in solution after centrifugation
at 100,000 g for 30 min, after disruption of the mitochondria by a
hypotonic shock followed by sonication (see Section 2). For this study,
we compared mitochondria isolated from a wild-type, a Δyfh1
mutant, a Δggc1 mutant, and a Δggc1 mutant overexpressing YFH1
on amulticopy plasmid (Δggc1-YFH1). Cells deleted for the GGC1 gene
accumulate iron in their mitochondria [34,35], as do Δyfh1 cells. The
level of Yfh1p in these different strains was estimated by western blot
(Fig. 4). There were about 1000 Yfh1p molecules per cell in the wild-
type, 800 in the Δggc1 mutant and 4500 in the Δggc1 mutant
overexpressing the YFH1 gene. Overexpressing YFH1 in Δggc1 cells did
not signiﬁcantly change the amount of total iron accumulated in the
cells and did not improve the respiration or growth of the cells, but
decreased the amount of oxidized proteins in the mitochondria, as
evidenced by oxyblots (data not shown). We puriﬁed the mitochon-
dria from these various strains grown with 1 µM 55Fe(III)-citrate, and
determined the amount of iron present in a soluble and insoluble form
(Fig. 5). Wild-type mitochondria contained about 20 nmol iron per
mg protein, more than half of which was present in a soluble form
(Fig. 5A). Mitochondria from the Δyfh1, Δggc1 and Δggc1-YFH1
mutant strains contained 70–100 nmol iron per mg protein, most of
which was insoluble (Fig. 5A). The small soluble fraction of iron was
probably overestimated, since disruption of the mitochondria was
achieved by sonication, which could lead to the release of some iron
from the insoluble pool into solution or pseudo-solution (small
micelles of iron which would not be recovered in the centrifugation
pellets). The amount of soluble iron in themitochondrial matrix of the
Δggc1 mutant was similar in cells overexpressing YFH1 (Fig. 5A). The
ratio of insoluble iron to soluble iron in the mitochondria was similar
for the three mutants (15- to 17-fold higher than in wild-type
mitochondria), and did not depend on the amount of Yfh1p (Fig. 5B).
Thus, mutations leading to iron accumulation in the mitochondria
(yfh1 or ggc1) also lead to iron precipitation in the matrix, regardless
of the amount of Yfh1p. Our results thus suggest that the protective
effect against protein oxidation in Δggc1 cells overproducing Yfh1p
did not result from direct iron chelation by Yfh1p. These ﬁndings were
consistent with results obtained from experiments described below
(Sections 3.4 and 3.5).
3.4. Mössbauer spectroscopy of whole mitochondria
We further analyzed the form of iron accumulated inmitochondria
isolated from mutant strains, grown with 10 µM 57Fe(III)-citrate,
using Mössbauer spectroscopy. For this study, we included an
additional strain, Δssq1, which is also known to accumulate
mitochondrial iron [36]. Consistent with previous observations [6],
the 4.2 K Mössbauer spectrum of Δyfh1 mitochondria (Fig. 6)
Fig. 5. Soluble and insoluble iron in the mitochondria of different strains. Cells were
grown overnight in deﬁned medium without copper and iron (Bio101). Copper was
added in the form of 5 µM CuS04, and iron as 1 µM 55Fe(III)-citrate. Mitochondria were
puriﬁed and soluble and insoluble fractions obtained by ultracentrifugation (100,000 g,
30 min) of the samples after hypotonic shock and sonication (see Section 2).
A. Absolute amounts of soluble (open bars), insoluble (dotted bars) and total (closed
bars) iron in the mitochondria of the different strains. B. Ratio of insoluble-to-soluble
iron in the same mitochondria. Results are from one representative experiment.
Fig. 7. Relative distribution of the internal magnetic ﬁeld at the iron nucleus as ﬁtted
from the applied ﬁeld Mössbauer spectra of Δyfh1 mutant yeast mitochondria.
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(1)mm/s,ΔEQ=0.63(2)mm/s and Γ=0.52/0.50(2)mm/s, typical of
a high-spin ferric iron bound to oxygen/nitrogen in an octahedral
arrangement. As discussed previously [6], the line-width broadening
and the Fe/P ratio of 1/2.9 [37] may be due to polydisperse
nanoparticles of ferric phosphate. Spectra recorded in applied
magnetic ﬁelds up to 7 T reﬂected a distribution of hyperﬁne ﬁelds,
similar to those observed by Lindahl et al. in their study of
mitochondria from Yah1p- and Atm1p-depleted cells [38,39]. The
central doublet of high ﬁeld spectra (Fig. 6) corresponded to about 1/
4 of the spectral area, indicating that the magnetic moments were
oriented in the direction of the applied ﬁeld. The variable ﬁeld spectra
were best ﬁtted using a near rectangular distribution of hyperﬁne
ﬁelds in the range 0 TbBhfb40 T (Fig. 7).
At both 4.2 K and 78 K, the same spectra were obtained for
mitochondria isolated from the Δssq1, Δggc1, and Δggc1-YFH1
mutants (Fig. 8). Similarly, these strains showed the same hyperﬁne
ﬁeld distribution in the presence of an applied magnetic ﬁeld. Similar
values for δ and ΔEQ have previously been reported for bacterial
Ferritin cores [40,41]. Unlike eukaryote ferritins, which display
magnetically-split spectra up to relatively high temperatures
(TB∼30 K), bacterial ferritins show paramagnetic transitions around
3 K. The lack of a magnetically ordered phase above temperatures of a
few Kelvins have been associated with a lower degree of crystallinity
and a higher phosphate content—hence longer Fe–Fe distances—of
bacterial ferritin cores [42,43]. We recorded spectra of mitochondria
from the yeast mutants at a temperature of 1.6 K. At this low
temperature we did not see any magnetic splitting, but observed a
broadening of the main doublet, suggesting the onset of a paramag-Fig. 6. Mössbauer spectra of Δyfh1 yeast mitochondria. Spectra were recorded at 4.2 K
in a magnetic ﬁeld of 7 T, applied parallel to the γ beam. The solid line results from a
simulation with δ=0.52 mm/s, ΔEQ=0.63 mm/s, and a Bhf distribution, as shown in
Fig. 8. The ﬁt was achieved assuming a hyperﬁne ﬁeld orientedwithin 10° parallel to the
applied ﬁeld. The best ﬁt to the data was obtained with an Euler angle β=56° between
the efg main axis and the direction of the applied ﬁeld.netic transition. This, and the high phosphate content of the
mitochondria, suggest that the degree of crystallinity of the
accumulated iron must be even lower than in bacterial ferritins.
Moreover, bacterioferritins display a narrow range of hyperﬁne ﬁelds
around 42 T [40,41], whereas all the mutant mitochondria we studied
showed a uniform distribution of Bhf in the range of 0 to 40 T. These
results are consistent with a model in which the accumulated iron is
not in the form of ferric cores of deﬁnite size encapsulated in protein
envelopes, but rather in the form of amorphous aggregates of ferric
phosphate randomly distributed in the mitochondria. Iron was under
the same chemical form in all the mutants studied even in the mutant
overexpressing YFH1. Mitochondria isolated from the Δggc1-YFH1
mutant yielded exactly the same Mössbauer spectrum as the other
mutants, with similar intensity. Thus, increasing the amount of Yfh1p
did not result in any measurable change in the amount or chemical
form of the iron accumulated in the mitochondria.
3.5. Analysis of soluble mitochondrial iron by FPLC
Most of the iron accumulated in the mitochondria of the mutant
strains was insoluble (Fig. 5). It is therefore possible that small
differences in the soluble mitochondrial iron pool of the different
strains were difﬁcult to detect by Mössbauer spectroscopy of whole
mitochondria. We thus further studied the composition of mitochon-
drial iron in the various strains by analyzing the matrix-soluble
fractions by gel ﬁltration, separating out the iron-binding proteins in
thematrix.Wild-type,Δyfh1, Δggc1 and Δggc1-YFH1 cells were grown
with 1 µM 55Fe(III)-citrate. Soluble mitochondrial fractions (matrix)
were puriﬁed and analyzed by FPLC on a gel ﬁltration column after
centrifugation at 25,000 g for 30 min. The elution patterns of iron for
the various strains are shown in Fig. 9A. In the four strains analyzed,
the soluble mitochondrial iron eluted in three main peaks, of
N670 kDa, 50 kDa and 15 kDa. A fourth peak of about 4 kDa was
present in the matrix of wild-type and Δyfh1 cells, but not in the
matrix of Δggc1 or Δggc1-YFH1 cells (Fig. 9A). The ﬁrst peak
(N670 kDa) probably corresponds to small particles/aggregates of
iron that were not completely removed by centrifugation and to iron
that was non-speciﬁcally associated with high molecular weight
protein complexes. The last peak (4 kDa) probably corresponds to
iron chelated by organic compounds. The two other peaks (50 kDa
and 15 kDa) probably correspond to iron speciﬁcally bound to iron-
binding protein(s), these peaks being resolved further by subsequent
anion-exchange chromatography (MonoQ; data not shown). For twoFig. 8.Mössbauer spectraofmitochondria fromdifferent yeast strains.Δggc1-YFH1 (A),Δggc1
(B),Δyfh1 (C),Δssq1 (D). Spectra recorded at 78 K in zero appliedmagneticﬁeld.Quadrupole
doublet ﬁtting gave δ=0.50mm/s and ΔEQ=0.61 mm/s for all spectra.
Fig. 9. Analysis by gel ﬁltration (FPLC) of the mitochondrial matrix from different
strains. Cells were grown overnight in deﬁned medium without copper and iron
(Bio101). Copper was added in the form of 5 µM CuS04, and iron as 1 µM 55Fe(III)-citrate.
Mitochondria were puriﬁed, subjected to hypotonic shock and sonicated before being
centrifuged (see Section 2). Supernatants (1 mg protein of mitochondrial matrix) were
loaded onto a Superdex 200 column, and elution fractions were analyzed for 55Fe content
by scintillation counting (A) or forYfh1pbywesternblotting (B). A. Thedistribution of 55Fe
after gelﬁltrationofmitochondrialmatrices isolated fromwild-type (closed circles),Δggc1
(open squares),Δggc1-YFH1 (closed squares) andΔyfh1 cells (open circles). B.Distribution
of Yfh1p after gel ﬁltration ofmitochondrialmatrices isolated fromΔggc1 andΔggc1-YFH1
cells. Fractions indicated by numbers (1–7) in A were pooled, concentrated and analyzed
by SDS-PAGE followed by western blotting.
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various molecular masses were analyzed by immunoblotting for
Yfh1p (Fig. 9B). Consistent with our ﬁndings from a previous study
[19], overexpressing YFH1 resulted in a higher level of frataxin
oligomerization in thematrix (Fig. 9B). However, although the level of
frataxin and the extent of its oligomerization differed between the
mitochondrial matrixes from Δggc1 and Δggc1-YFH1 cells, the pattern
of iron elution from the gel ﬁltration column was qualitatively and
quantitatively identical for these two samples (Fig. 9A). We also
detected peaks at 50 kDa and 15 kDa, although with different
intensities, in the eluate from the Δyfh1mitochondrial matrix sample
(Fig. 9A). Thus, none of these peaks seemed to be due to iron bound to
Yfh1p.
4. Discussion
In yeast, the lack of the frataxin homolog Yfh1p results in a marked
accumulation of iron in the mitochondria [44,45]. This iron is
generally considered to be the cause of the hypersensitivity to
oxidative stress in frataxin-deﬁcient cells (reviewed in [9]), which
thus assumes that it accumulates in a redox-active form. However,
many different yeast mutants, most of which with impaired [Fe–S]
cluster assembly, accumulate large amounts of iron in their
mitochondria, as observed forΔyfh1 cells, despite these othermutants
expressing a functional frataxin [46]. Additionally, these mutant
strains show differing levels of sensitivity to oxidative stress. The lack
of frataxin is thus not the speciﬁc and the only cause of mitochondrial
iron accumulation and, conversely, mitochondrial iron accumulation
cannot be the cause of all the phenotypes observed in frataxin-
deﬁcient cells. Therefore, to investigate a potential link between
hypersensitivity to oxidative stress and mitochondrial iron accumu-
lation in Δyfh1 cells, the phenotypes of other mutants, which also
accumulate mitochondrial iron but produce a functional Yfh1p, also
need to be taken into account. In one insightful study by Yang et al.[47], the authors compared the forms of iron between mitochondria
from various yeast strains, based on assessing the ability of iron to
displace manganese in Sod2p (“Sod2p-reactive iron”). They found
that iron was Sod2p-reactive in some strains (Δmtm1, Δssq1 and
Δgrx5), but not in Δyfh1 [47]. This result can be interpreted as
evidence that Yfh1p is required for inactivation of Sod2 by metal
replacement [47], but may also be due to iron being less reactive in
Δyfh1 mitochondria than in the mitochondria of other mutants. The
study by Yang et al. [47] opened up the possibility that iron may
accumulate in slightly different forms in the mitochondria of different
mutants. Our data do not exclude this possibility. Indeed, our analyses
of the soluble pools of mitochondrial iron, as analyzed by gel ﬁltration,
showed quantitative differences between the Δyfh1 and Δggc1 strains
(more iron in the 50 kDa peak obtained for Δggc1 than for Δyfh1
mitochondria, for example). However, both mutants showed peaks of
iron at the same position (50 kDa and 15 kDa), showing that Yfh1p
was not involved in the generation of these peaks. The same can be
concluded for the comparison between the Δggc1 and theΔggc1-YFH1
strains: for these strains, the elution proﬁles of soluble iron were
quantitatively and qualitatively undistinguishable, despite Yfh1p
being overproduced (ﬁve times the wild-type level) in one strain
and not in the other. Moreover, Mössbauer spectroscopic analysis of
whole mitochondria from Δyfh1, Δssq1, Δggc1 and Δggc1-YFH1 cells
did not reveal any difference in the forms of iron accumulated
between mitochondria of these different strains. We previously
showed by the same technique that iron accumulated in Δyfh1
mitochondria as amorphous nanoparticles of ferric phosphate,
unavailable biologically [6]. In this study, we found the same to be
true for other iron-accumulating mutants, Δssq1 and Δggc1, regard-
less of the amount of Yfh1p present. Similar ﬁndings have also been
described for other yeast mutants accumulating iron in the mito-
chondria, yah1 and atm1 [38,39]. Thus, although we cannot exclude
the possibility that small, undetectable differences exist between
strains, which cannot be detected by the methods employed, iron
accumulates mostly in the same precipitated amorphous form in the
mitochondria of different mutants, irrespective of Yfh1p abundance. It
is possible that our experimental conditions were not optimal for the
observation of ferritin-like frataxin particles. Indeed, oligomerization
of Yfh1p has been shown to occur under particular conditions in vivo,
for example in cells that overexpress monomeric Yfh1p, or that are
exposed to heat stress or conditions that increase iron inﬂux into the
mitochondria [18]. We have also noted that increasing the level of
YFH1 expression results in an increase in the level of Yfh1p
oligomerization ([19] and present work). However, there is no
evidence demonstrating that higher levels of iron are associated
with the formation of larger Yfh1p oligomers in vivo, despite studies
showing that Yfh1p assembly requires the presence of Fe2+ and is
dependent on iron concentration in vitro [14,18,32]. Rather, we found
that a shift in the level of Yfh1p oligomerization in vivo was not
accompanied by a shift in the distribution of soluble iron ([19] and
present work). Moreover, we overexpressed Yfh1p monomers in cells
that accumulate iron in their mitochondria (Δggc1), these two
conditions (overexpression and increased iron inﬂux) having been
shown previously to induce Yfh1p oligomerization [18], but we did
not detect any trace of ferritin-like frataxin particles using various
experimental methods. The possibility remains, however, that the
iron accumulated in Δggc1 mitochondria is not accessible for binding
by Yfh1p, as we don't know if iron accumulation/precipitation in the
Δggc1 mutant occurs downstream or upstream to a putative iron-
binding step by Yfh1p (which could result in a form of iron no longer
suitable for binding by Yfh1p, i.e. precipitated ferric phosphate). This
question is illustrated in Fig. 10.
In another approach, we investigated whether we could provide
evidence of Yfh1p acting as an iron storage protein in vivo through
quantitative evaluation. Frataxin has been functionally compared to
ferritin [14,33], but ferritin is abundant in mammals, whereas frataxin
Fig. 10. A schematic representation of questions raised by our work. The mitochondrial
membranes, with the putative Mrs3/4 iron transporters, and the fate of intra-
mitochondrial iron are represented. A. Wild-type. Iron enters the mitochondria, via the
Mrs3/4 mitochondrial carrier proteins, as Fe2+ (presumably) or Fe3+ (Fen+) and is
chelated by one or several unknown compound(s) (FeX1 and FeX2), before being used for
heme synthesis and [Fe–S] cluster assembly. Yfh1p, which is required for efﬁcient iron use
in the mitochondria, might be involved in different steps of these processes (as an iron-
binding protein, and/or an iron storage protein and/or a chaperone protein). GTP, which is
imported into themitochondria via the GTP/GDP carrier Ggc1p, is also required for [Fe–S]
assembly. Proper [Fe–S] cluster assembly is required to avoid massive iron import in the
mitochondria (through a mechanism that remains to elucidate, which we schematized in
the form of a negative retro-control of [Fe–S] clusters on mitochondrial iron import). B.
Δyfh1. In the absence of Yfh1p, [Fe–S] cluster assembly is impaired, leading to
increased iron import in the mitochondria. This iron precipitates with phosphates,
maybe after an oxidation step. Whether this iron precipitates immediately after its
uptake or after subsequent step(s) of binding is not known. C. Δggc1-YFH1. The lack of
GTP results in [Fe–S] cluster assembly impairment, leading to increased iron import in
the mitochondria. Overproduction of Yfh1p does not prevent precipitation of this iron
in the form of ferric phosphate. If iron is available for binding by Yfh1p from the ﬁrst
step of its uptake, Yfh1p is not an iron storage protein. If precipitation of iron occurred
upstream to the binding step by Yfh1p, there is a possibility that the precipitated iron
is no more available for binding by Yfh1p (dotted arrows).
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concentration of about 1000 molecules per cell in most growth
conditions [19]. Even at this low concentration, Yfh1p is in large
excess relative to the cell requirements. Indeed, Yfh1p levels can be
signiﬁcantly reduced without any adverse effect on cell growth
[30,32]. We observed that less than 100 molecules of Yfh1p per cell
were sufﬁcient to restore aconitase activity and to signiﬁcantly reduce
the amount of oxidatively modiﬁed protein in the mitochondria
(compared to frataxin-deﬁcient cells). At these levels of Yfh1p, the
number of soluble iron atoms in the mitochondrial matrix was
between 1000 and 5000 times greater than the number of Yfh1p
molecules. This greatly exceeds the iron-binding capacity of Yfh1p,
the iron-to-Yfh1p ratio in the multimeric iron storage form of Yfh1p
generally being considered not to exceed 50 [14,15]. As we noted in aprevious study [19], the fact that Yfh1p can fulﬁll the cell require-
ments at very low concentration is consistent with a catalytic role
played by this protein—probably involving its transient association
with iron.
These various observations suggest that Yfh1p does not play a
major role, if any, in mitochondrial iron storage. Our conclusion is
consistent with the ﬁndings of Aloria et al. [32], who showed that a
mutant Yfh1p defective in iron-induced oligomerization in vitro was
able to functionally replace the wild-type protein, even when
produced at very low levels. Previous observations that the expression
of human mitochondrial ferritin in Δyfh1 yeast cells attenuates the
deleterious phenotypes of this mutant seem also to be inconsistent
with our ﬁndings [48,49]. This interesting result does not mean,
however, that ferritin functionally replaced frataxin in these experi-
ments. It is possible that expression of ferritin in other iron-
accumulating mutants that have normal levels of Yfh1p would also
improve cell viability. Iron accumulation in mutant mitochondria
results in iron precipitation, yielding biologically unavailable ferric
particles, with a paradoxically smaller pool of soluble, available iron
than in wild-type mitochondria. Thus, although the mutant mito-
chondria are full of iron, the cells behave as if they were iron-deprived
(for example, inducing the iron regulon) [50]. Iron chelation by
ferritin in these mutant mitochondria may make more iron available
for biological processes, regardless of the function of Yfh1p,
potentially explaining the beneﬁcial effect of ferritin expression. It is
also possible that the soluble iron pool in mutant mitochondria,
although containing a smaller amount of iron than in wild-type
mitochondria, has a higher level of redox activity, which would also
explain the positive effect of iron chelation by ferritin. Finally, if
ferritin exerted its beneﬁcial effects on the physiology of Δyfh1 cells
by replacing an iron storage function of Yfh1p, wewould expect Yfh1p
overproduction to have beneﬁcial effects in cells that overaccumulate
iron in their mitochondria for reasons other than the lack of frataxin.
However, we did not ﬁnd this to be the case in Δggc1 cells.
An important question thus remains: what mechanism underlies
the sensitivity of Δyfh1 cells to oxidative stress? Most of the
accumulated iron in Δyfh1 mitochondria is precipitated, oxidized
and amorphous. This iron is therefore probably no more redox-active
than it is bioavailable. However, it is possible that the soluble iron,
although present in a smaller amount in Δyfh1 than in wild-type
mitochondria, could be more bioavailable in Δyfh1 mitochondria.
Additionally, even if Yfh1p does not store large amounts of iron in
vivo, its interaction with iron may still play an essential role in its
function. There does not seem to be any doubt, however, that the lack
of frataxin also leads, at least in part, to iron-independent sensitivity
to oxidative stress. In human, frataxin-deﬁcient cells are unable to
properly recruit antioxidant defense mechanisms [8], probably due to
impaired nuclear translocation of the Nrf2 transcription factor [51]. In
yeast, preventing iron accumulation in themitochondria ofΔyfh1 cells
(by excess zinc in the medium or by iron chelation) does not decrease
the sensitivity of cells to oxidative stress [24,52]. Conversely, some
suppressor strains, derived from Δyfh1 mutants by spontaneous
mutation, still accumulate iron in their mitochondria but show
increased resistance to oxidative stress [6]. Finally, frataxin-deﬁcient
Candida albicans cells (ΔCayfh1/Δ) are much more sensitive to
oxidative stress than S. cerevisae Δyfh1 cells, but accumulate much
less iron in the mitochondria [22]. The link between iron accumula-
tion and oxidative stress sensitivity in frataxin-deﬁcient cells (and in
other iron-accumulating mutants) is not straightforward, and clearly
requires further investigation.
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